Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Delivra Health BrandsDHBUF +9.14% Debt-to-Equity is 0.79 as of Mar. 2026, which is 88% above its 10-year median of 0.42. The stock has 3 warning signs investors should review. Among 812 Drug Manufacturers companies, Delivra Health Brands ranks worse than 80.67% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Delivra Health Brands's Debt-to-Equity or its related term are showing as below:
DHBUF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.42 Max: 0.79
Current: 0.79
During the past 13 years, the highest Debt-to-Equity Ratio of Delivra Health Brands was 0.79. The lowest was 0.00. And the median was 0.42.
DHBUF's Debt-to-Equity is ranked worse than 80.67% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs DHBUF: 0.79
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Delivra Health Brands Debt-to-Equity Related Terms
Delivra Health Brands Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Delivra Health Brands's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Delivra Health Brands's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delivra Health Brands Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Delivra Health Brands's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Delivra Health Brands's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delivra Health Brands (DHBUF) has a Debt-to-Equity of 0.79 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Delivra Health Brands and its competitors. This is 88% above median its historical median of 0.42. According to the industry distribution chart, Delivra Health Brands ranks #655 out of 812 companies in the Drug Manufacturers industry, placing it in the top 80.7%.
Is Delivra Health Brands' Debt-to-Equity too high?
Delivra Health Brands' current Debt-to-Equity of 0.79 is 88% above median its 10-year median of 0.42. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Delivra Health Brands' value of 0.79 is 192.6% above this industry median. Based on the distribution chart, Delivra Health Brands ranks #655 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Delivra Health Brands' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Delivra Health Brands ranks #655 out of 812 companies for Debt-to-Equity. This places Delivra Health Brands in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Delivra Health Brands' value of 0.79 is 192.6% above this benchmark. While the company's 10-year median is 0.42 vs. the industry median of 0.27, Delivra Health Brands has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delivra Health Brands's current Debt-to-Equity of 0.79 is 192.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Delivra Health Brands and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delivra Health Brands's current Debt-to-Equity is 0.79, which is 88% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delivra Health Brands stock overvalued right now?
Based on GuruFocus' analysis, Delivra Health Brands (DHBUF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.08 — trading 55.3% below its estimated fair value. The current Debt-to-Equity is 0.79, which is 88% above median its 10-year median of 0.42 and 192.6% above the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Delivra Health Brands (DHBUF), the current Debt-to-Equity is 0.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Delivra Health Brands Inc helping people take control of health with alternative wellness solutions. Its portfolio features brands like Dream Water and LivRelief that deliver relief from common, everyday issues like chronic pain, anxiety, and sleeplessness. The principal activities of the company are to provide lifestyle and health and wellness products to consumers and patients in regulated markets. The company geographically operates in Canada and United States, out of which it generates maximum revenue from Unites States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHBUF has been successfully added to your 
